GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...
China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...
A small prospective, double-blind study in children with IgE-mediated cow’s milk allergy (CMA) found that heated cow’s milk ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
TipRanks on MSN
Apogee Therapeutics reports positive Phase 1b asthma results
Apogee Therapeutics ( ($APGE) ) has provided an announcement. On January 6, 2026, Apogee Therapeutics reported positive interim results from a ...
London-based drugmaker GSK has announced the UK approval of Nucala (mepolizumab) as an add-on maintenance biologic treatment ...
GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...
Background Exacerbations are major causes of morbidity in individuals with chronic respiratory diseases such as chronic ...
Dr Lata BichileMK, a 42-year-old engineer, walked into my OPD along with his wife in August 2023. He had been experiencing ...
Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...
(Alliance News) - GSK PLC on Monday said mepolizumab, sold under the brand name Nucala, has been approved in China for use in adults with chronic obstructive pulmonary disease. The London-based ...
Statins were linked to decreased risk for acute asthma exacerbations in mild asthma and had a significant protective effect in Black patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback